Alligator Bioscience AB (publ) (STO:ATORX)

Market Cap	131.59M +98.6%
Revenue (ttm)	520.00K -99.0%
Net Income	-41.56M
EPS	-0.26
Shares Out	628.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,480,882
Average Volume	10,468,688
Open	0.2095
Previous Close	0.2095
Day's Range	0.2040 - 0.2160
52-Week Range	0.1570 - 7.2100
Beta	1.24
RSI	47.67
Earnings Date	May 5, 2026

About Alligator Bioscience AB

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has comple...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ATORX

Financial Performance

In 2025, Alligator Bioscience AB's revenue was 839,000, a decrease of -98.55% compared to the previous year's 57.72 million. Losses were -51.35 million, -78.05% less than in 2024.